Explore
Validate
LearnPAB18270
antibody from Abnova Corporation
Targeting: BCL2L1
Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB18270 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB18270, RRID:AB_10716807
- Product name
- BCL2L1 polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic peptide of BCL2L1.
- Storage
- Store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2.
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Dai Y, Dent P, Grant S
Molecular pharmacology 2003 Dec;64(6):1402-9
Molecular pharmacology 2003 Dec;64(6):1402-9
Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2.
Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J, Ziółkowska M, Ferrari-Lacraz S, Strom TB, Maśliński W
Journal of immunology (Baltimore, Md. : 1950) 2002 Aug 15;169(4):1760-7
Journal of immunology (Baltimore, Md. : 1950) 2002 Aug 15;169(4):1760-7
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C, Kim CN, Fang G, Bhalla KN
Blood 2000 Feb 1;95(3):1014-22
Blood 2000 Feb 1;95(3):1014-22
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot analysis of extracts from 293 cells, treated with UV (30 mins), using BCL2L1 polyclonal antibody (Cat # PAB18270).Peptide "+" means "peptide blocking".
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of HeLa cells, using BCL2L1 polyclonal antibody (Cat # PAB18270).Peptide "+" means "peptide blocking".
- Validation comment
- Immunofluorescence
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using BCL2L1 polyclonal antibody (Cat # PAB18270).Peptide "+" means "peptide blocking".
- Validation comment
- Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
